This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Recharge Your Portfolio With Altair

Life Beyond Batteries

Altair's fortunes aren't tied solely to its ability to bring a battery to market.

Spectrum Pharmaceuticals (SPPI - Get Report) agreed to license Altair's RenaZorb, which is used to treat hyperphosphatemia, or high phosphorus levels in the blood, of end-state renal disease patients. RenaZorb, which uses Altair's lanthanum nanomaterial technology, is evidence of Altair's diverse product platform. The deal provides Altair with 100,000 shares of restricted Spectrum shares, the purchase of $200,000 worth of Altair shares by Spectrum, and undisclosed milestone payments based on future clinical and sales goals.

Altair notched $1.2 million in sales in 2004, a small amount to be sure, but the total was a marked improvement from the $73,000 in sales the company generated in 2003. That said, the company has a solid balance sheet and recently took advantage of its surge in market value to sell 5 million shares, bringing its total cash balance to $31 million with virtually no debt. This should be enough to allow Altair to bring a product to the market within the next few years.

There is a lot of hope built into Altair's stock at its current $200 million market cap. But with just 43 million shares outstanding and no analyst coverage, Altair's shares could rally meaningfully on good news and an increased media following, as its battery technology moves from a great idea to a marketable product.

Based upon our conversations with sources familiar with the company, we wouldn't be surprised to hear a partnership announced within the next three months, which could push shares over the $5 mark and in front of institutional investors who ordinarily shy away from low-dollar stocks. Given the inherent risk with the stock, though, we would look to pare any losses near the $3.80-a-share level, or 9% below the stock's current quote.
William Gabrielski is a research associate at TheStreet.com and is accredited with a Series 7 license. In keeping with TSC's editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks.

David Peltier is a research associate at TheStreet.com In keeping with TSC's editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Peltier welcomes your feedback and invites you to send your comments to david.peltier@thestreet.com .
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ALTI $0.55 0.00%
SPPI $6.98 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs